Figure 4.
Summarized scheme with proposed acting targets of anti-SARS-CoV-2 in the replication cycle of the virus. Inhibitors of cell entry: inhibitors of angiotensin-converting enzyme 2 (ACE2Is) and antimalarial drugs: chloroquine, hydroxychloroquine; inhibitors of transmembrane protease/serine subfamily member 2 (TMPRSS2): camostate; Inhibitors of replication, membrane fusion, and assembly of SARS-CoV-2: remdesivir, lopinavir/ritonavir combination, umifenovir; humanized monoclonal antibody IgG1 anti-human receptor for interleukin-6 (IL-6): tocilizumab.